Menu
Search
|

Menu

Close
X

Inovio Pharmaceuticals Inc INO.OQ (NASDAQ Stock Exchange Global Select Market)

4.43 USD
-0.06 (-1.34%)
As of 9:00 PM BST
chart
Previous Close 4.49
Open 4.48
Volume 151,481
3m Avg Volume 215,198
Today’s High 4.50
Today’s Low 4.36
52 Week High 8.44
52 Week Low 3.77
Shares Outstanding (mil) 90.23
Market Capitalization (mil) 600.01
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.75 Mean rating from 4 analysts

KEY STATS

Revenue (mm, USD)
FY18
2
FY17
42
FY16
35
FY15
41
EPS (USD)
FY18
-0.358
FY17
-1.064
FY16
-1.004
FY15
-0.440
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.75
Price to Sales (TTM)
vs sector
11.57
5.71
Price to Book (MRQ)
vs sector
4.18
5.37
Price to Cash Flow (TTM)
vs sector
--
23.33
Total Debt to Equity (MRQ)
vs sector
0.00
16.44
LT Debt to Equity (MRQ)
vs sector
0.00
12.17
Return on Investment (TTM)
vs sector
-53.08
14.38
Return on Equity (TTM)
vs sector
-55.75
16.07

EXECUTIVE LEADERSHIP

Avtar Dhillon
Non-Executive Chairman of the Board, Since 2011
Salary: $296,314.00
Bonus: $59,535.00
Jong Kim
President, Chief Executive Officer, Director, Since 2009
Salary: $643,579.00
Bonus: $371,566.00
Peter Kies
Chief Financial Officer, Since 2002
Salary: $385,573.00
Bonus: $144,514.00
Niranjan Sardesai
Chief Operating Officer, Since 2012
Salary: $409,715.00
Bonus: $156,311.00
Mark Bagarazzi
Chief Medical Officer, Since 2010
Salary: $408,458.00
Bonus: $156,311.00

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

6769 Mesa Ridge Rd
SAN DIEGO   CA   92121-2995

Phone: +1858.4103134

Inovio Pharmaceuticals, Inc. (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company's DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases. It has completed, current or planned clinical programs of its SynCon immunotherapies for human papillomavirus (HPV)-caused pre-cancers and cancers, influenza, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus (HCV), hepatitis B virus (HBV), human immunodeficiency virus (HIV), Ebola, Middle East Respiratory Syndrome (MERS) and Zika virus. With its immunotherapy platform, as well as with its CELLECTRA electroporation delivery technology, it has a pipeline of pre-clinical and clinical stage products that have generated in vivo immune responses.

SPONSORED STORIES